<DOC>
	<DOCNO>NCT00557622</DOCNO>
	<brief_summary>This single-blind , placebo-controlled , parallel group study evaluate efficacy BRL29060A ( paroxetine hydrochloride hydrate , hereafter paroxetine ) administer orally dose range 20 mg 50 mg daily supper 12 week Japanese patient posttraumatic stress disorder ( PTSD ) assess change baseline CAPS-SX total score . Also effect paroxetine regional cerebral blood flow ( rCBF ) induce subthreshold emotional arousing ( symptom stimulating ) task determine use functional magnetic resonance imaging ( fMRI ) exploratory assessment correlation change rCBF efficacy . The sample size 30 subject . The study period consist 4 week run-in phase , 12 week treatment phase , 0-3 week taper phase follow-up examination 2 week last dose , total 18-21 week . Subjects visit clinic start run-in phase , Week -2 , start treatment phase , Weeks 2 , 4 , 6 , 8 12 treatment , follow-up examination .</brief_summary>
	<brief_title>Clinical Evaluation BRL29060A ( Paroxetine Hydrochloride Hydrate ) Posttraumatic Stress Disorder ( PTSD )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Stress Disorders , Traumatic</mesh_term>
	<mesh_term>Stress Disorders , Post-Traumatic</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<criteria>Patients primarily diagnose PTSD ( Posttraumatic Stress Disorder : 309.81 ) use DSMIVTR criterion . The CAPSDX ( ClinicianAdministered PTSD ScaleDX ) M.I.N.I . ( The Mini International Neuropsychiatric Interview , Japanese version 5.0.0 . [ 2003 ] ) use diagnosis Pathologic condition : Patients experience motor vehicle accident ( MVA ) severe potential severe physical injury 3 month ago less 12 month ago Patients age 20 &lt; 65 time signing Informed consent Male female patient Inpatient/outpatient status : Both permit Patients able give write informed consent person ( i.e. , patient capable give write informed consent ) Patients whose combine score CAPSSX standard B , C , D 50 Patients primarily diagnose DSMIVTR Axis I disorder PTSD ( e.g . major depressive disorder , dysthymic disorder , specific phobia [ simple phobia ] , obsessivecompulsive disorder , panic disorder , etc . ) within 6 month week 4 ( start baseline phase ) Patients present current major depressive episode precede diagnosis PTSD Patients receive disability payment due PTSD psychiatric disease Patients currently engage compensation litigation whereby personal gain would achieve prolonged symptom PTSD psychiatric disorder Patients meet DSMIVTR criterion substance abuse dependence ( alcohol drug ) within 6 month Week 4 ( start baseline phase ) Patients history suicide attempt within 6 month Week 4 ( start baseline phase ) , , opinion investigator , `` C. high risk suicide '' accord MINI Week 4 Patients pregnant , lactate childbearing potential likely become pregnant Patients receive electroconvulsive therapy ( ECT ) prior Week 4 ( start baseline phase ) Patients receive another investigational product within 12 week Week 4 ( start baseline phase ) Patients history complication manic psychosis Patients history complication convulsive disorder ( epilepsy , etc . ) Patients diagnosis complication cognitive disorder ( MMSE &lt; =24 point ) Patients history complication serious cerebral organic disorder . ( e.g . cerebrovascular disorder , meningitis , degenerative disease neurological disorder seizure ; however , bleed upper arachnoid membrane exclude ) Patients unable unwilling undergo fMRI procedure ( e.g. , cerebrovascular clipping surgery , pacemaker , internal metal magnetism , claustrophobia ) Patients glaucoma Patients known tendency bleed predisposing condition Patients history hypersensitivity paroxetine Patients serious physical symptom ( cardiac , hepatic renal dysfunction , hematopoietic dysfunction , etc. ) . For seriousness , Grade 3 `` Criteria seriousness adverse reaction drug , etc . ( Yakuan No.80 ) '' use index Patients history complication cancer malignant tumour Patients chronic hepatitis type B and/or C positive hepatitis B surface antigen ( HBsAg ) and/or hepatitis C antibody Others investigator subinvestigator considers ineligible unable participate investigation Criteria Week 0 ( start Treatment Phase ) : Subjects whose drug compliance rate Drug 1 ( Runin Phase placebo ) &lt; 80 % Week 4 Week 0 ; Subjects whose CAPSSX total score standard B , C , D Week 0 vary 25 % compare Week 2</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>PTSD ( Posttraumatic Stress Disorder )</keyword>
	<keyword>CAPS</keyword>
	<keyword>fMRI</keyword>
	<keyword>Paroxetine</keyword>
</DOC>